novo nordisk semaglutide nash seeks approval for for the treatment of MASH Novo Nordisk's weight-loss pill wins

Applications Received for Device Pass-Through Status for CY 2026 We received eight complete applications by the March 3, 2025, quarterly deadline, which was the last quarterly deadline for applications to be received in time to be included in the CY 2026 OPPS/ASC proposed rule

While many people initially explore GLP-1 therapy for weight-related goals, our approach focuses more broadly on improving metabolic function and long-term health markers

This injectable medication works by mimicking the action of a hormone called glucagon-like peptide-1 (GLP-1), which helps regulate blood sugar levels

Han SH, Safeek R, Ockerman K, et al

Once symptoms improve, the dose may be raised again more slowly

Real-world instances of cost difficulties encountered by individuals seeking these treatments further highlight the urgent requirement for solutions in this domain